Researchers develop blood test for stress

Published Date: 08 Mar 2023

Researchers at Indiana University School of Medicine have developed a blood test for stress. This test assesses a person's risk of stress,...

Read Full News

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

6 Psychiatry Headlines You Missed in January 2026

FDA Examines Generative AI in Psychiatry, With Hans Eriksson, MD, PhD Hans Eriksson, MD, PhD

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Utilizing Alcohol Use Disorder Pharmacotherapy in Hepatology, With Hersh Shroff, MD, MPA Hersh Shroff, MD, MPA

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

The Skin–Brain Axis: Emerging Evidence Transforming Dermatologic Care Lisa A. Swanson, MD, Enzo Berardesca, MD, Mohammad Jafferany, MD

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

Todays Updates

From Pathology to Precision: The Story of Leukemia Therapy

From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care evolved from near-certain death to precise, life-extending therapies.

Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer

Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe bone pain. A new study suggests a simple solution.

Todays Updates

From Pathology to Precision: The Story of Leukemia Therapy

From 19th century ‘white blood’ observations and pathological anatomy to the discovery of BCR-ABL and imatinib, leukemia care evolved from near-certain death to precise, life-extending therapies.

Delaying Pegfilgrastim May Curb Bone Pain in Breast Cancer

Pegfilgrastim helps prevent myelosuppression in women undergoing chemotherapy for breast cancer but can also cause severe bone pain. A new study suggests a simple solution.

Latest News

Delay Discounting Fails to Predict MDD Relapse, Q&A With Giles Story, PhD

6 Psychiatry Headlines You Missed in January 2026

As mental health AI tools rise, the FDA weighs benefits and risks, emphasizing oversight and performance testing. Eriksson discusses AI in psychiatric care.

Shroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.

Research reveals a significant skin-brain connection, linking inflammatory skin diseases to neurocognitive and emotional health, particularly in children with atopic dermatitis.

FDA Accepts NDA for Priority Review of Centanafadine to Treat Adult, Pediatric ADHD

News All Time

Psychiatry in 2025: Year in Review

Psychiatry in 2025: Year in Review

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Teva Pharmaceuticals Submits NDA on TEV-‘749 for Schizophrenia to the FDA

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43

4 Psychiatry Headlines You Missed in November 2025

4 Psychiatry Headlines You Missed in November 2025

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Single Dose of MM120 (LSD) Shows Lasting Anxiety Reduction in GAD: Phase 2b Results Chelsie Derman

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD Chelsie Derman

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Prenatal Opioid Pain Medications Likely Not Linked to Autism or ADHD Risk Chelsie Derman

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

Atopic Eczema Linked to Suicidal Ideation in Global Study of 30,000 Adults Chelsie Derman

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

FDA Initiates Acetaminophen Label Change, Leucovorin Approval for Cerebral Folate Deficiency Abigail Brooks, MA

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

Daily Ammoxetine at 40, 60 mg Outperforms Placebo for MDD in Phase 2 Trial Chelsie Derman

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

APhA, Coalition of Autism Scientists Cite Insufficient Data to Support Acetaminophen, Autism Link Abigail Brooks, MA

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

5 Psychiatry Headlines You Missed in September 2025 Chelsie Derman

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Recommended News For You

Early Identification of Ovarian Cancer; Allergy Medicine for NSCLC? Unfavorable Development for Anti-TIGIT Medication?

Who Bears the Cost of "Forever Chemical" Cleanup?

Reducing social media to an hour a day boosts young people's self-image.

An Intimate Life of Medical Innovation and Charity.

AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma

Kidney cancer: Understanding what a renal cell carcinoma diagnosis means

Parents, teachers at Missouri school want answers after string of cancer diagnoses

Recommended Articles For You

Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer 

Unlocking the Secrets of Hemoglobin: How It Works to Keep Us Healthy 

Understanding Acute Intermittent Porphyria: Symptoms, Diagnosis and Treatment 

The Statistical Horizon of Colorectal Cancer: From Global Trends to Precision Therapies and Colorectal Cancer 2025 Forecasts 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Molecular profiling of renal medullary carcinoma identifies TROP2 as a promising therapeutic target

2.

FDA Approves New Drug Combo for RR Multiple Myeloma

3.

November 2023, Medical Bulletin 04/.

4.

I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.

5.

FDA approves Blenrep for relapsed or refractory multiple myeloma

1.

From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma

2.

Understanding Vaso Occlusive Crisis: Symptoms, Causes, and Management Strategies

3.

The Unseen Danger of Anal Cancer: How to Protect Yourself

4.

Sorafenib: Understanding the science behind a powerful cancer drug 

5.

Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Blood Cancer- Further Discussion on Genomic Testing & Advancement in Diagnosis and Treatment

2.

Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment

3.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V

4.

Virtual Case Study on Pedal Edema and Triple Vessel Disease - An Initiative by Hidoc Dr.

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot